5,978 Shares in Enovis Co. (NYSE:ENOV) Bought by Avidian Wealth Enterprises LLC

Avidian Wealth Enterprises LLC purchased a new position in Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 5,978 shares of the company's stock, valued at approximately $262,000.

A number of other institutional investors have also recently made changes to their positions in ENOV. UMB Bank n.a. lifted its position in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. lifted its position in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after buying an additional 300 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Enovis during the third quarter worth approximately $55,000. FMR LLC raised its position in Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Enovis in the third quarter valued at $217,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Trading Up 0.3 %

Shares of NYSE ENOV traded up $0.15 during trading on Tuesday, reaching $44.04. The stock had a trading volume of 191,311 shares, compared to its average volume of 995,498. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The business's 50-day moving average price is $45.30 and its 200-day moving average price is $44.33. The company has a market cap of $2.50 billion, a P/E ratio of -20.11 and a beta of 1.94.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a "buy" rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $64.83.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.